Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients | Zendy

Rannakoe Lehloenya | Zendy; Sipho Dlamini | Zendy; Rudzani Muloiwa | Zendy; Betty Kakande | Zendy; Mzudumile R. Ngwanya | Zendy; Gail Todd | Zendy; Keertan Dheda | Zendy

Open Access

Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients

Author(s) -

Rannakoe Lehloenya,

Sipho Dlamini,

Rudzani Muloiwa,

Betty Kakande,

Mzudumile R. Ngwanya,

Gail Todd,

Keertan Dheda

Publication year - 2016

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofw130

Subject(s) - rifabutin , medicine , rifampicin , tuberculosis , human immunodeficiency virus (hiv) , virology , mycobacterium avium complex , rifapentine , mycobacterium tuberculosis , pathology , latent tuberculosis , clarithromycin , helicobacter pylori

Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research